250–500 mg/day (up to 2 g in clinical studies).
Improves memory and attention in age-related or vascular cognitive decline.
View the study (RCT) →The large ICTUS trial showed no clear benefit on recovery after a stroke.
See the study (large RCT (ICTUS)) →Possible neuroprotective effect on the optic nerve.
View the study (systematic review) →⏱ 3 min read
Citicoline, known chemically as CDP-choline or cytidine-5'-diphosphocholine, is a molecule that the body makes naturally and that serves as a key intermediate in the synthesis of phosphatidylcholine, the main structural phospholipid of neuronal membranes; when taken as a supplement it is hydrolyzed into cytidine and choline, which cross the blood-brain barrier and reassemble inside the brain to fuel the production of membrane phospholipids and acetylcholine, the central neurotransmitter of memory and attention.
It is one of the few cognitive supplements with a formal clinical indication in some countries: in Spain, Italy, and several Asian countries it is prescribed as Somazina or equivalents for cognitive impairment associated with aging and for post-stroke recovery, with clinical data supporting its use in those specific contexts, although U.S. regulation keeps it solely as a dietary supplement without a formal medical indication.
The indication with the best clinical evidence is the acute and subacute phase of ischemic stroke: several randomized trials and meta-analyses have shown that doses of 500 to 2,000 milligrams per day for 6 to 12 weeks improve functional neurological recovery, with modest but significant effects on scales such as the modified Rankin Scale or the NIH Stroke Scale; the ICTUS trial, the largest to date, did not replicate the spectacular benefits of earlier studies and lowered expectations about the real magnitude of the effect.
Despite the more disappointing result of ICTUS, citicoline remains part of clinical protocols in countries such as Spain, where it is considered a reasonable adjunct with an excellent safety profile that can be combined with standard neurological rehabilitation without interfering with other pharmacological stroke treatments.
In older people with mild cognitive impairment or incipient vascular dementia, doses of 1,000 milligrams per day for 6 to 12 months have shown improvements in episodic memory, attention, processing speed, and executive function in several randomized trials, with an effect that appears to be related to better availability of phospholipids to maintain the integrity of neuronal membranes and cholinergic synaptic transmission.
In healthy young adults, the data are more limited and the effects on "normal" cognition are small or nonexistent, suggesting that citicoline works better when there is a clinical situation affecting neuronal integrity (aging, ischemic damage, trauma) than in people with healthy brains at the peak of their capacity.
In glaucoma, several studies have explored the use of oral or topical citicoline as an optic nerve neuroprotectant, with results suggesting a reasonable adjunctive role alongside standard intraocular pressure-lowering treatment; in cocaine addiction, several small trials have shown modest effects on withdrawal symptoms and craving, in a line of research that remains open.
In moderate to severe head trauma, the studies are heterogeneous and the evidence is less solid than in stroke, but the excellent safety profile allows its use as an adjunct in many neurological rehabilitation services, especially in subacute phases where the combination with occupational and cognitive therapy appears to amplify functional benefits.
The effective doses in clinical trials range from 250 to 2,000 milligrams per day, divided into two doses, for weeks or months depending on the indication; it is well absorbed orally and has high bioavailability, with no need to take it with food; perceptible clinical effects usually appear between 4 and 12 weeks, and it is not an immediate-acting compound.
Citicoline has an exceptionally good safety profile: adverse effects are rare and mild (digestive discomfort, headache, insomnia), and no relevant drug interactions or serious cases of toxicity have been described, even with prolonged use at high doses; it is one of the safest cognitive supplements available, which makes it especially attractive for older people on multiple medications, in whom the risk of interactions with other nootropics is a concern.
Information, not medical advice. Scientific evidence reflects the quality of the studies.